PETER KOVLER and JUDY LANSING KOVLER are chairman and president, respectively, of the Judy and Peter Blum Kovler Foundation. The foundation focuses its attention on biomedical research, historical memorials and museums, and the unmet needs of immigrants and the underserved. Peter Kovler serves as a member of the National Advisory Board of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and is a former chair of the Pancreatic Cancer Action Network. Judy Kovler is chair of the Sibley Memorial Hospital Foundation Board where she has served since 2018, leading the philanthropic support for Sibley Memorial Hospital as part of Johns Hopkins in the National Capital Region. She is also a member of the Board of Directors of the Foundation for the National Institutes of Health. Judy was treated for breast cancer at Sibley Memorial Hospital in 2018. The Kovlers established the Peter and Judy Kovler Professorship in Breast Cancer Research in the Department of Pathology in honor of her treatment team and in recognition of the support for these and many other programs at Johns Hopkins Medicine.
The Peter and Judy Kovler Professorship in Breast Cancer Research
School of Medicine
Established in 2020 by the Judy and Peter Blum Kovler Foundation
Held by Andrea Richardson
ANDREA RICHARDSON, M.D., Ph.D., is the inaugural Peter and Judy Kovler Professor in Breast Cancer Research. She was recruited to the Johns Hopkins Departments of Pathology and Oncology in 2015 as an associate professor and to serve as the director of breast pathology and the director of pathology for the National Capital Region. In these leadership roles, she has helped integrate the three-hospital National Capital Region division of the Department of Pathology into a cohesive and unified group of talented pathologists. On the clinical front, Dr. Richardson maintains a pathology practice at Sibley Memorial Hospital. She is recognized as an expert in the genetics and pathobiology of breast cancer. Her research is focused on characterizing the molecular aberrations that define clinically important subtypes of breast cancer. In particular, she has made major contributions to the development of novel tissue-based molecular assays to guide therapy for women with breast cancer. Dr. Richardson is considered a leader in her field, frequently invited to present at regional, national, and international conferences in the areas of molecular pathology and breast cancer pathology, and has co-authored more than 140 peer-reviewed publications and articles.